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Abstract Rapidly generated high-titer Semliki Forest virus
(SFV) vectors can infect numerous mammalian cell lines and
primary cell cultures, and result in high levels of transgene
expression. SFV-based expression of transmembrane receptors
has been characterized by specific ligand-binding activity and
functional responses. Adaptation of the SFV technology for
mammalian suspension cultures has allowed the production of
hundreds of milligrams of recombinant receptor for purification
and structural studies. The same SFV stock solutions used
for the infection of mammalian cells in culture have also been
successfully applied for efficient transgene expression in
organotypic hippocampal slices, as well as in vivo in rodent
brain. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Recombinant protein expression is today a prerequisite for
basic research and modern drug discovery. The completion of
the sequencing of the human genome has further accelerated
the demand for rapid and e⁄cient production of recombinant
protein. It is therefore no surprise that intensive development
on various expression systems has resulted in novel and im-
proved gene delivery vectors. A major issue has been the ex-
pression system to be used. It has become evident that there is
no universal perfect system applicable to each recombinant
protein of interest. Expression vectors developed for Escheri-
chia coli, yeast and insect cells have shown high expression of
many recombinant proteins. However, more complex mam-
malian proteins require speci¢c factors and chaperone pro-
teins for correct folding and transport, and are subjected to
di¡erent post-translational modi¢cation processes. In at-
tempts to circumvent these problems for non-mammalian ex-
pression vectors, de¢ned epitopes and transmembrane regions
have been deleted or modi¢ed. Alternatively, only extracellu-
lar domains have been expressed or fusions made to well-ex-
pressed bacterial proteins. The use of mammalian expression
vectors to produce functional proteins, by contrast, is another
approach. Unfortunately, mammalian expression vectors have
generally resulted in low recombinant protein yields and, ad-
ditionally, have been time-consuming and labor-intensive to
use.
Replication-de¢cient alphavirus vectors, speci¢cally Semliki
Forest virus (SFV) and Sindbis virus vectors, have become
attractive alternatives for rapid and high-level gene delivery
[1,2]. Alphavirus vectors were engineered to allow the expres-
sion of topologically di¡erent proteins in a broad range of
mammalian host cells [3]. Here, we review various applica-
tions of SFV vectors for both in vitro and in vivo gene deliv-
ery. We describe the use of SFV vectors for the expression of
several G protein-coupled receptors (GPCRs) and ligand-
gated ion channels. Because of their strong preference for
neuronal infection in the central nervous system, SFV vectors
are favorable for expression and localization studies in dis-
persed primary neurons in culture, as well as in organotypic
hippocampal slices. Moreover, SFV vectors e⁄ciently deliver
genes to the rat brain in vivo, and preliminary studies in
animal tumor models have generated encouraging anti-tumor
responses. We also summarize the development of novel, im-
proved SFV vectors.
2. Expression of recombinant receptors in cell lines
SFV vectors have been applied for the expression of s 50
di¡erent GPCRs [4]. In many instances, extremely high levels
of expression have been achieved, as measured by speci¢c
binding activity on intact cells or isolated membranes. Bmax
values of up to 150 pmol receptor/mg protein, and receptor
densities of s 5 000 000 receptors/cell have been obtained.
SFV-mediated GPCR expression in various cell lines showed
some variation in expression levels, which interestingly de-
pended on the time of post-infection (Fig. 1). For instance,
expression of the human neurokinin-1 receptor (hNK1R) in
Chinese hamster ovary (CHO) cells demonstrated maximal
speci¢c agonist-binding activity at 12 h post-infection [5],
whereas baby hamster kidney (BHK) cells infected with
SFV vectors carrying the hamster K1b adrenergic receptor
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showed a much later peak of expression, i.e. at 40 h post-
infection [6]. Likewise, the highest levels of rat histamine H2
receptor expression in COS-7 cells were reached at 40 h after
infection [7]. The di¡erent expression patterns mainly corre-
sponded to the individual features of the expressed GPCRs,
although some variations in expression levels occurred be-
tween di¡erent host cell lines.
Functional coupling of SFV-expressed GPCRs to G pro-
teins has been demonstrated by measuring intracellular Ca2
release, inositol triphosphate accumulation, cAMP stimula-
tion, and GTPQS binding. As described for the agonist-bind-
ing activity, functional responses also followed a time-depen-
dent expression pattern [5], most likely due to SFV-induced
inhibition of host cell protein synthesis and apoptosis. Addi-
tionally, the unfavorable ratio between exogenous receptor
and endogenous G proteins, due to the extreme receptor over-
expression and inhibition of endogenous G protein synthesis,
contributes to the decrease in functional activity observed
with time. The limited amount of endogenous G proteins,
however, can be compensated for by SFV-mediated co-expres-
sion of G protein subunits [6].
SFV vectors have also been applied for the expression of
ligand-gated ion channels [8,9]. Extreme levels of speci¢c ago-
nist-binding activity were obtained for the mouse serotonin
5-HT3 receptor and the rat and human p2X purine receptors.
Additionally, functional ATP-induced responses were demon-
strated for these channels by electrophysiological recordings
[8,9] and Ca2 measurements [10].
The adaptation of SFV technology to mammalian cells in
suspension cultures has signi¢cantly facilitated the production
of large quantities of recombinant receptors [11]. Infection of
BHK cells in a bioreactor of 11.5 l resulted in the production
of 20 mg 5-HT3 receptor (Bmax value of 52 pmol receptor/mg
protein, 3.2U106 receptors/cell) [10]. The production was
highly reproducible (yields of 1^2 mg receptor/l) and allowed
e⁄cient puri¢cation and preliminary characterization of the
C-terminal hexa-histidine-tagged 5-HT3 receptor [12]. The pu-
ri¢cation of the receptor, veri¢ed by SDS^PAGE, yielded a
single 65 kDa polypeptide, which is in good agreement with
the postulated size of the glycosylated 5-HT3 receptor subunit.
Deglycosylation reduced the size to 49 kDa. Furthermore, the
puri¢ed receptor showed a speci¢c ligand-binding activity of
V5 nmol/mg protein for [3H]GR65630. Secondary structure
determinations by circular dichroism indicated mainly K-heli-
ces (50%) and L-strands (24%), and minor contributions from
non-regular structures (9%). Size exclusion chromatography
suggested a molecular mass of 280 kDa for the functional
receptor complex, which is in good agreement with the postu-
lated pentameric structure. Preliminary cryo-electron micros-
copy studies on the puri¢ed 5-HT3 receptor also suggested a
channel structure consisting of ¢ve subunits.
To further improve the receptor-expression capacity of SFV
vectors, a fusion construct to the SFV capsid gene was engi-
Fig. 1. Time-dependent SFV-mediated expression of GPCRs in
mammalian host cells. BHK-21, CHO-K1 and COS-7 cells were in-
fected with SFV vectors encoding the human neurokinin-1 receptor
(hNK1R), the hamster K1b adrenergic receptor (haAR-1b) and the
rat histamine H2 receptor (rH2R), respectively. Saturation binding
on isolated membranes was performed with [3H]substance P
(hNK1R) [4], [125I]HEAT (haAR-1b) [6] and [125I]iodoaminopoten-
tidine (rH2R), as previously described [7].
Fig. 2. SFV capsid fusion protein for enhancement of recombinant
protein expression. The presence of a translation-enhancement signal
in the capsid sequence results in increased expression levels of SFV
p62 and E1 polyproteins. Furthermore, the capsid protein is auto-
catalytically cleaved from the fusion protein. Similarly, the fusion of
the full-length capsid sequence to the hNK1R enhances transgene
expression by ¢ve- to 10-fold, and results in the e⁄cient cleavage of
the capsid-hNK1R fusion protein. HF-tags, FLAG-tag and hexa-
histidine tag.
Fig. 3. Metabolic labeling of BHK-21 cells infected with recombi-
nant SFV. BHK-21 cells were infected with SFV vectors expressing
the hNK1R (lane 1) or the hNK1RHF as a capsid fusion (lane 2),
and labeled with [35S]methionine at 16 h post-infection. Cell lysates
were subjected to 10% SDS^PAGE and visualized by autoradiogra-
phy.
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neered. Similar to the Sindbis virus [13], it has been reported
earlier that the 5P-end of the capsid gene contains a trans-
lation-enhancement signal, which can increase transgene ex-
pression levels by ¢ve- to 10-fold [14]. Upon fusing the full-
length capsid sequence to the transgene, it was observed that
recombinant proteins were e⁄ciently cleaved o¡ by the auto-
catalytic cleavage activity of the capsid protein. To enhance
the expression levels of the hNK1R, a fusion to the full-length
capsid sequence was engineered (Fig. 2). A hexa-histidine-tag
and a FLAG-tag were introduced at the C-terminus to facil-
itate receptor puri¢cation and identi¢cation, respectively. The
generated SFV construct yielded approximately ¢ve-fold high-
er receptor levels when compared to the hNK1R expressed
from the SFV vector lacking the capsid sequence [4]. Further-
more, the fusion protein was e⁄ciently cleaved into the capsid
and hNK1R proteins (Fig. 3). Large-scale production of
hNK1R in serum-free CHO cell suspension cultures resulted
in 5^10 mg of receptor protein/l culture. Cell-fractionation
studies revealed that although the majority (80%) of the
recombinant receptors was located in internal structures,
the receptors showed functional binding of hNK1R ligands.
The puri¢cation of hundreds of milligrams of hNK1R has
been achieved and preliminary structural studies are in prog-
ress.
3. Gene delivery to neurons in primary cultures and
hippocampal slices
Alphavirus vectors have generally shown a strong prefer-
ence for infection of neurons [15]. Recombinant SFV particles
have therefore been used to e⁄ciently deliver genes into dis-
persed primary neurons in culture [16]. The infection rate is
impressively high and ranges between 75 and 95%. Even when
primary hippocampal neurons were cultured on a feeder layer
of glial cells, s 90% of the infected cells were neurons [17].
SFV-infected neurons were intact for several days post-infec-
tion, and SFV-mediated expression of metabotropic glutamate
receptors resulted in the functional inhibition of voltage-gated
calcium currents [18].
Similar to cultures of dissociated cells, SFV vectors both
e⁄ciently and preferentially infect neurons in organotypic sli-
ces prepared from the hippocampus of 6-day-old rats [19,20].
At 1^2 days post-infection, s 90% of the transduced cells
were either pyramidal cells or interneurons. Similar results
were obtained with the closely related Sindbis virus [19,21].
Fig. 4 shows an example of CA1 pyramidal cells expressing
soluble green £uorescent protein (GFP; top panels) and a
GFP fusion of the gap-junction-forming membrane protein
connexin 36 (bottom panels). For both transgenes, the wild-
Fig. 4. Recombinant SFV-mediated gene transfer into CA1 pyramidal cells of cultured rat hippocampal slices. A,B: Expression of GFP, as re-
vealed by £uorescence microscopy, in slices ¢xed at 14 days in culture and 2 days after injection of 100-fold diluted wild-type SFV-GFP (A)
and 10-fold diluted SFV(PD)-GFP (B). C,D: Expression of rat connexin 36 fused to GFP (Cx36-GFP) in slices ¢xed at 14^15 days in culture
and 2 days after injection of wild-type SFV-Cx36-GFP (C) and 3 days after injection of SFV(PD)-Cx36-GFP (D). Note the punctuate GFP
£uorescence staining pattern in infected cells. Abbreviations: so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; scale bar =
40Wm.
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type SFV vector and the less cytotoxic SFV(PD) mutant (see
below) were used. As expected, the observed GFP staining
pattern is similar for both forms of the SFV vector. The
time course of GFP expression in cultured slices, however,
was transient and showed a peak at 1^2 days post-infection
for both wild-type SFV and SFV(PD) [20]. Present forms of
SFV are therefore useful for short- rather than long-term gene
expression. In any case, cell-viability experiments showed that
electrophysiological properties of SFV-infected neurons seem
normal at 2 days post-infection [20], and s 90% of the in-
fected cells appear intact at 5 days post-infection, as they
exclude propidium iodide [19]. Compared to other, more com-
monly used, viral vectors derived from adenovirus, adeno-as-
sociated virus, and lentivirus, recombinant SFV is preferred
for rapid, high-level and neuron-speci¢c transgene expression
[20].
4. Gene delivery to speci¢c brain regions
One advantage of alphavirus vectors is that stocks of the
same replication-de¢cient virus particles used to infect cell
lines in culture can also be applied in vivo without any addi-
tional puri¢cation or concentration. Sindbis virus expressing
L-galactosidase injected into the nucleus caudata/putamen and
nucleus accumbens septi of mice resulted in a transient report-
er gene expression [22]. Similarly, injection of SFV-LacZ par-
ticles into the striatum and amygdala of rat brain caused a
local, high-level L-galactosidase expression [23]. The viral in-
jection had no impact on the general behavior of the rats up
to 28 days post-injection, as monitored by food intake, body
weight, body temperature, muscle strength, sensorimotor
function, and exploratory behavior. Similar to our data in
cultured hippocampal slices, maximal transgene expression
was obtained at 1^2 days post-injection, and L-galactosidase
levels declined thereafter. In situ hybridization data con¢rmed
the transient nature of gene expression. Obviously, alphaviral
vectors are therefore not suitable, at least in their present
form, for studies where long-term expression is required. In
contrast, short-term gene expression can be desirable in some
applications, e.g. when the e¡ect of gene expression on behav-
ior has to be monitored before, during, and after the over-
expression of the protein.
5. Animal models for cancer gene therapy
Because SFV vectors, as described above, have demon-
strated a transient expression pattern both in vitro and in
vivo, they can be considered as potentially attractive for can-
cer gene therapy applications. In this context, favorable fea-
tures of the SFV system are the enormous RNA replication in
the cytoplasm that results in extreme transgene expression
levels, and the ability to induce apoptosis in infected cells,
which has been seen in rat glioma and gliosarcoma cell lines
[24], as well as in human prostate tumor cell lines [25]. Re-
cently, SFV vectors have been injected intratumorally to study
therapeutic e⁄cacy in two mouse tumor models. SFV vectors
expressing both the p40 and p35 subunits of interleukin-12
(IL-12) from the same vector, using two subgenomic SFV
26S promoters, were injected into a B16 mouse melanoma
model and monitored for tumor regression by Doppler ultra-
sonography [26]. SFV-mediated IL-12 expression resulted in
signi¢cant tumor regression and inhibition of tumor blood
vessel formation. Moreover, repeated injections resulted in
enhanced anti-tumor response, but did not elicit any SFV-
related antibody response. In another study, empty SFV vec-
tors, or vectors expressing reporter genes (SFV-LacZ and
SFV-GFP) were injected into human lung carcinoma that
had been implanted into nude mice [27]. Signi¢cant tumor
regression was observed after injecting SFV vectors on three
consecutive days, followed by another three injections a week
later.
6. Vector development
Although SFV vectors have a broad application range,
there are two features that limit, to some extent, their use.
First, the transient nature of expression, due to the instability
of the viral genomic RNA molecules, is a drawback if long-
term expression is desired. Prolongation of expression could
also improve the expression yields, particularly for secreted
proteins. Second, the high cytotoxicity of SFV vectors for
host cells will to some extent limit transgene expression due
to premature cell death. The dramatic shut-down of host cell
protein synthesis and the induction of apoptosis certainly re-
stricts the host cell viability after SFV infections. This e¡ect
clearly limits studies on expression kinetics and signal trans-
duction pathways.
For this reason, less cytotoxic alphavirus vectors have been
developed. A single point mutation in the non-structural pro-
tein gene nsP2 of Sindbis virus resulted in a non-cytopatho-
genic phenotype [28]. Unfortunately, this phenotype was ob-
served only in very few cell lines, and viral RNA replication
and expression levels were reduced, resulting in lower trans-
gene expression. We recently reported a less cytotoxic SFV
vector, SFV(PD), with two point mutations in the nsP2
gene [29]. Interestingly, compared to the wild-type SFV vec-
tor, SFV(PD) caused a seven- to 10-fold higher GFP and
L-galactosidase expression, and permitted a substantially pro-
longed survival of many mammalian host cell lines and of
dissociated hippocampal neurons. Upon infection with
SFV(PD), host cell protein synthesis is only slightly a¡ected,
and the induction of apoptosis is delayed (Lundstrom, unpub-
lished results). In addition to SFV(PD), we have engineered
novel SFV vectors with both non-cytopathogenic and temper-
ature-sensitive phenotypes [30]. These vectors showed no or
reduced transgene expression at the non-permissive temper-
ature (36^37‡C), but caused extreme levels of overexpressed
protein at a lower temperature (31‡C). Recently, a novel mu-
tant vector with a single point mutation in the nsP2 gene was
obtained after transfecting BHK cells with SFV vectors con-
taining randomly mutagenized SFV non-structural genes up-
stream of a neo-resistance gene [31]. This SFV vector was
replication persistent, demonstrated very low cytotoxicity,
and resulted in a signi¢cantly prolonged duration of transgene
expression.
7. Conclusions
SFV vectors have now been used for various in vitro and in
vivo applications. The relatively large cloning capacity (5^8
kb) [20], the easy and rapid generation of high-titer virus
stocks (s 109 infectious particles/ml) [32] and the broad
host range have made these vectors attractive. The extremely
high expression levels obtained for GPCRs and ion channels
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have signi¢cantly facilitated the production of large quantities
of membrane proteins. This has opened up new possibilities
for advanced structural biology studies on membrane recep-
tors. Moreover, SFV vectors have shown their high capacity
to infect neurons in primary cell cultures and in brain slices,
which allows the examination of gene function in the central
nervous system. Recently, SFV vectors have been applied in
vivo and have resulted in encouraging therapeutic responses in
tumor models without detectable anti-viral side e¡ects. Fur-
ther vector development has generated novel non-cytopatho-
genic, as well as temperature-sensitive SFV mutants that will
extend the SFV application range. Studies on expression ki-
netics and signal-transduction events, as well as ribozyme and
antisense technologies, should now be feasible with these new
SFV vectors.
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